![logo](/logos/IBT-B.ST.webp)
Infant Bacterial Therapeutics AB (publ)
SSE:IBT-B.ST
93.4 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Infant Bacterial Therapeutics AB (publ) |
Symbool | IBT-B.ST |
Munteenheid | SEK |
Prijs | 93.4 |
Beurswaarde | 1,215,890,540 |
Dividendpercentage | 0% |
52-weken bereik | 41.3 - 106.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Staffan Stromberg Ph.D. |
Website | https://www.ibtherapeutics.com |
An error occurred while fetching data.
Over Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)